The safety and efficacy of tripotassium dicitrato bismuthate (De-Nol) maintenance therapy in patients with duodenal ulceration
- PMID: 2104081
- DOI: 10.1111/j.1365-2036.1990.tb00460.x
The safety and efficacy of tripotassium dicitrato bismuthate (De-Nol) maintenance therapy in patients with duodenal ulceration
Abstract
Seventy-one patients whose duodenal ulcers had healed after a 4-week treatment period with tripotassium dicitrato bismuthate (TDB) were randomly allocated to receive maintenance treatment with either one TDB swallow tablet nocte (equivalent to 120 mg Bi2O3) or an identical placebo. During 12 months of follow-up, no side-effects were reported by TDB-treated patients, blood bismuth levels did not rise above discontinuation threshold concentrations (greater than 50 micrograms/L in the first 6 months, or greater than 100 micrograms/L in the second 6 months), and there were no adverse effects on haematological or biochemical indices. Ulcer relapse was significantly less in TDB-treated patients (P less than 0.025). Cumulative relapse rates at 6 and 12 months were 51% and 66%, respectively, for placebo-treated patients and 26% and 31%, respectively, for those who received TDB. It is likely that TDB is a safe and effective maintenance treatment for patients with duodenal ulcer disease.
Similar articles
-
Healing and recurrence of duodenal ulcer after treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine.Gut. 1986 Jan;27(1):106-10. doi: 10.1136/gut.27.1.106. Gut. 1986. PMID: 3512382 Free PMC article. Clinical Trial.
-
Randomised crossover trial of tripotassium dicitrato bismuthate versus high dose cimetidine for duodenal ulcers resistant to standard dose of cimetidine.Gut. 1984 Jul;25(7):703-6. doi: 10.1136/gut.25.7.703. Gut. 1984. PMID: 6376292 Free PMC article. Clinical Trial.
-
Effects of tripotassium dicitrato bismuthate (TDB) tablets or cimetidine in the treatment of duodenal ulcer.Gut. 1983 Dec;24(12):1148-51. doi: 10.1136/gut.24.12.1148. Gut. 1983. PMID: 6357964 Free PMC article. Clinical Trial.
-
Review article: safety of bismuth in the treatment of gastrointestinal diseases.Aliment Pharmacol Ther. 1996 Aug;10(4):459-67. doi: 10.1046/j.1365-2036.1996.22163000.x. Aliment Pharmacol Ther. 1996. PMID: 8853750 Review.
-
[Bismuth preparations in the treatment of patients with gastric and duodenal ulcer disease].Klin Med (Mosk). 2008;86(9):57-63. Klin Med (Mosk). 2008. PMID: 19048841 Review. Russian.
Cited by
-
A requiem for vagotomy.BMJ. 1991 Apr 6;302(6780):846. BMJ. 1991. PMID: 1867677 Free PMC article. No abstract available.
-
Comparative pharmacokinetics of bismuth from ranitidine bismuth citrate (GR122311X), a novel anti-ulcerant and tripotassium dicitrato bismuthate (TDB).Eur J Clin Pharmacol. 1994;47(2):177-80. doi: 10.1007/BF00194969. Eur J Clin Pharmacol. 1994. PMID: 7859806 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
